Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D3 receptor ligands

Journal of Medicinal Chemistry

Volumn 45, Issue 26, 2002, Pages 5727-5735

  Leopoldo, Marcello ^a   Berardi, Francesco ^a   Colabufo, Nicola A ^a   De Giorgio, Paola ^a   Lacivita, Enza ^a   Perrone, Roberto ^a   Tortorella, Vincenzo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; AMIDE; BENZAMIDE DERIVATIVE; BP 897; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; N [2 [4 (4 CHLOROPHENYL)PIPERAZIN 1 YL]ETHYL]3 METHOXYBENZAMIDE; N [4 (4 PIPERAZIN 1 YL)BUTYL]CARBOXAMIDE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 7 METHOXY 2 BENZOFURANCARBOXAMIDE; N [4 [4 (2,3 DIMETHYLPHENYL)PIPERAZIN 1 YL]BUTYL] 3 METHOXYBENZAMIDE; NGB 2904; PRAMIPEXOLE; RECEPTOR SUBTYPE; ROPINIROLE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG STRUCTURE; LIPOPHILICITY; POSITRON EMISSION TOMOGRAPHY; RECEPTOR AFFINITY; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZAMIDES; BENZOFURANS; CELL LINE; CEREBRAL CORTEX; HIPPOCAMPUS; HUMANS; LIGANDS; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037137596     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020952a     Document Type: Article

References (38)

1. 3) as a target of neuroleptics. Nature 1990, 347, 72-76.
2. 3 dopamine receptor. Arzneim.-Forsch./Drug Res. 1992, 42, 224-230.
3. 3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 2001, 90, 231-259.
4. Schwartz, J. C.; Levesque, D.; Martres, M. P.; Sokoloff, P. Dopamine D3 receptor: Basic and clinical aspects. Clin. Neuropharmacol. 1993, 16, 295-314.
5. Caine, S. B.; Koob, G. F. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 1993, 260, 1814-1816.
6. 3 receptor agonist. Nature 1999, 400, 371-375.
7. 3 receptor. Eur. J. Pharmacol. 2000, 407, 47-51.
8. Halldin, C.; Gulyas, B.; Langer, O.; Farde, L. Brain radioligands - State of the art and new trends. Q. J. Nucl. Med. 2001, 45, 139-152.
9. Pilowsky, L. S. Probing targets for antipsychotic drug action with PET and SPET receptor imaging. Nucl. Med. Commun. 2001, 22, 829-833.
10. 3 receptors. Abstr. Soc. Neurosci. 2000, 2154 (abstract no. 809.9).
11. 4 ligand. J. Med. Chem. 1998, 41, 4903-4909.
12. 4 receptor ligand. J. Med. Chem. 2000, 43, 270-277.
13. 3 receptor partial agonists. Bioorg. Med. Chem. Lett. 1996, 6, 1361-1366.
14. 3 receptor. Bioorg. Med. Chem. Lett. 1995, 5, 219-222.
15. 3 dopamine receptor ligands. Bioorg. Med. Chem. Lett. 1997, 7, 2403-2408.
16. 3 receptor antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 2715-2718.
17. 3 receptor antagonist with high oral bioavailability and CNS penetration in the rat. J. Med. Chem. 2000, 43, 1878-1885.
18. ClogP 4.0 (Version for Windows); BioByte Corp.: Claremont, CA.
19. 3 receptor ligands. J. Med. Chem. 2001, 44, 1815-1826.
20. 3 receptor agonist. Nature 1999, 400, 371-375.
21. 3 receptor. Bioorg. Med. Chem. Lett. 1997, 7, 1995-1998.
22. Brown, H. C.; Choi, Y. M.; Narasimhan, S. Selective reductions. 29. A simple technique to achieve an enhanced rate of reduction of representative organic compounds by borane-dimethyl sulfide. J. Org. Chem. 1982, 47, 3153-3163.
23. 1A antagonist research. Drugs Future 1993, 18, 631-642.
24. Prelog, V.; Driza, G. J. The N-monoarylpiperazines and their derivatives. Collect. Czech. Chem. Commun. 1941, 6, 211-224.
25. Ishizumi, K.; Kojima, A.; Antoku, F. Synthesis and anxiolytic activity of N-substituted cyclic imides (1R*,2S*,3R*,4S*)- N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3-bicyclo [2.2.1]heptane-dicarboximide (tandospirone) and related compounds. Chem. Pharm. Bull. 1991, 39, 2288-2300.
26. Janssen, P. A. J.; 1-(2-Thienyl)-3-[4-(2-pyridyl)piperazine]-1-propanol. U.S. Patent 2,973,360; Chem. Abstr. 1961, 55, 17668i.
27. Chen, X. Preparation of 1-(isoquinolin-1-yl)-4-(1-phenylmethyl)-piperazines as dopamine receptor subtype specific ligands. U.S. Patent 6008352, 1999.
28. Rognan, D.; Mann, A.; Wermuth, C. G.; Martres, M. P.; Giros, B.; Sokoloff, P.; Schwartz, J. C.; Lecomte, J. M.; Garrido, F. Preparation of N-[heterocyclyl(alkyl)]-2-naphthamides as dopaminergic antagonists. Eur. Pat. Appl. EP 539281, 1993.
29. Bretscher, E.; Rule, H. G.; Spence, J. Optical activity and the polarity of substituted groups. Part IX. Menthyl esters of methoxynaphthoic and of diphenyl-2-carboxylic acids. J. Chem. Soc. 1928, 1493-1504.
30. Norman, M. H.; Navas, F., III. Piperazine and piperidine derivatives, and their use as antipsychotics. PCT Int. Pat. Appl. WO 9316073, 1993.
31. 1A and D-2 receptor affinity of o-methoxyphenylpiperazine derivatives with terminal benzamide fragment on N-4 alkyl chain. 2. Farmaco 1995, 50, 505-510.
32. Wu, Y.; Smith, K. R.; Rayburn, J. W.; Kissel, J. W. Psychosedative agents. N-(4-Phenyl-1-piperazinylalkyl)-substituted cyclic imides. J. Med. Chem. 1969, 12, 876-881.
33. 4, dopamine receptors revealed in transfected neuronal cell lines. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 649-653.
34. 4 antagonists. J. Med. Chem. 1996, 39, 1946-1948.
35. 1A receptor full agonist in rat cerebral cortex. Naunyn. Schmiedebergs Arch. Pharmacol. 1995, 352, 276-282.
36. Glossmann, H.; Hornung, R. α-Adrenoceptors in rat brain: Sodium changes the affinity of agonists for prazosin sites. Eur. J. Pharmacol. 1980, 61, 407-408.
37. GraphPad Prism Software (Version for Windows); GraphPad Software, Inc.: San Diego, CA.
38. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.